Compare EMF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EMF | MOLN |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.9M | 164.2M |
| IPO Year | N/A | 2021 |
| Metric | EMF | MOLN |
|---|---|---|
| Price | $16.66 | $4.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 29.3K | 4.2K |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.58 | $3.36 |
| 52 Week High | $12.67 | $5.91 |
| Indicator | EMF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 49.23 |
| Support Level | $16.20 | $4.20 |
| Resistance Level | $16.62 | $4.60 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 23.42 | 45.59 |
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.